AstraZeneca & MedImmune in the news.

AstraZeneca focuses on Alzheimer's hunt
Drugs firm expands research teams worldwide to crack potentially lucrative market
Julia Kollewe
The Guardian, Monday 15 October 2012 17.21 BST

"....One of the main difficulties drug treatments for the brain have to overcome is the "blood brain barrier" – the makeup of the brain's blood supply protects it from most infection, but that also keeps out larger molecules such as antibiotics and antibodies. "Blood-brain barrier penetration is the holy grail" for diseases like Alzheimer's, declares Jane Osbourn, site leader for AstraZeneca's biologics arm MedImmune based in Cambridge in Britain...."


Full-time PhD Studentship
Department of Life, Health and Chemical Sciences;
circulation date : 22/10/2012
closing date : 16/11/2012

Applications are invited for a full-time PhD Studentship for three years (with a stipend of £13,590 annually) from 1 January 2013:

The development of a drug delivery system using brain endothelial-specific non-antibody binding domains as transport carriers; Faculty of Science

The blood-brain barrier is a major obstacle for many drugs that potentially target the central nervous system (CNS). The general aim of the project is to develop a drug delivery system that is able to cross the blood-brain barrier at therapeutically relevant concentrations....

....The project involves cross-disciplinary research at the interface between biology and chemistry. This studentship also aims to create links between academia and industry and as such this project is sponsored by MedImmune, one of the world's leading biotechnology companies....